Date: 2012-02-28
Type of information: Company acquisition
Acquired company: Anabasis (italy)
Acquiring company: Dompé (italy)
Amount:
Terms: In January 2011, Anabasis signed a licensing and co-development agreement with Dompé, which acquired a 49% stake in Anabasis and patent rights for the use of NGF to treat neurotrophic keratitis (NK). By the end of 2011 Dompé has successfully achieved the development of a stable process suitable for industrial production of recombinant human NGF (rhNGF) at its biotechnological plant based in L’Aquila (Italy), which operates in compliance with GMPs and is authorized to produce recombinant proteins for human use.
Under the terms of the agreement, Dompé has become the sole shareholder of Anabasis by acquiring remaining 51% of its share capital for an undisclosed amount, including an immediate upfront and subsequent milestone payments related to the development and commercialization of NGF in pathological conditions.
Details: Dompé has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.
Anabasis, founded in 1999 by a group of Italian scientists who were among the first to study the use of Nerve Growth Factor (NGF) – research which won Rita Levi-Montalcini the Nobel Prize – has advanced an ophthalmic formulation of NGF to preclinical and clinical stages for various diseases affecting both the anterior part of the eye, such as neurotrophic keratitis and dry eye, as well as the posterior part of the eye such as retinitis pigmentosa and glaucoma.
Related: Ophtalmological diseases
